

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



MEDICARE PLAN PAYMENT GROUP

TO: All Part D Plan Sponsors

FROM: Cheri Rice, Director
Medicare Plan Payment Group

SUBJECT: Modification of Prescription Drug Event (PDE) editing of Cialis for Benign Prostatic Hyperplasia (BPH)

DATE: August 2, 2013

On May 27, 2012, CMS began accepting PDEs for the drug, Cialis, when used for the treatment of BPH with dates of service (DOS) on or after October 6, 2011. The dosing of the PDEs could not be more than 1 tablet per day at the 5 mg strength or 2 tablets per day at the 2.5 mg strength. If this dosing was exceeded, the PDE would receive edit code 745 stating "Medicare does not pay for this drug for this strength and/or daily supply".

CMS has become aware of PDEs being accepted for dosing below 1 tablet per day at the 5 mg strength or 2 tablets per day at the 2.5 mg strength which does not correspond with the treatment of BPH. For instance, PDEs stating 6 tablets of 5mg strength with a 30 day supply does not correlate with treatment of BPH, but with the treatment of erectile dysfunction which is excluded from Part D coverage. In response, the editing for PDEs for Cialis is being modified.

CMS will only accept Cialis PDEs with a total daily dosage of 5mg per day or 2.5 mg per day (to allow for renal function adjustments) in the 5mg and 2.5mg strengths. Specifically, PDEs will be accepted with 1 tablet per day at the 5mg strength, or 1- 2 tablets per day at the 2.5mg strength.

Edit 745 will continue to be issued for PDEs that exceed this dosing. With this editing modification, edit 745 will also be issued for PDEs that are below this dosing.

Plans should review any previously accepted Cialis PDEs for appropriateness for the treatment of BPH.